Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
TIMOLIDE 10-25 is a fixed-dose combination tablet containing timolol maleate (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic), approved in 1981 for hypertension management. The combination leverages complementary mechanisms: timolol reduces heart rate and contractility while hydrochlorothiazide promotes sodium and fluid excretion. It is indicated for patients requiring dual antihypertensive therapy.
As a 40+ year-old product nearing loss of exclusivity with moderate competitive pressure (30), brand teams are likely focused on cost containment and transitioning to generic support rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TIMOLIDE presents limited career growth opportunities given its mature, LOE-approaching status with zero current linked job postings. Roles on this product focus on legacy management, generic transition, and compliance rather than innovation or market expansion.
Worked on TIMOLIDE 10-25 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.